Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Vitamin B12 Supplementation on Glycaemic Control in Uncontrolled Hyperhomocysteinemic Type 2 Diabetic Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02540642
Recruitment Status : Completed
First Posted : September 4, 2015
Last Update Posted : March 15, 2018
Sponsor:
Information provided by (Responsible Party):
Dr Yogendra Keche, Smt. Kashibai Navale Medical College and General Hospital

Brief Summary:

Increased plasma homocysteine level is associated with macroangiopathy and nephropathy in type 2 diabetes. Also increased levels of serum homocysteine are associated with microalbuminuria which is associated with increased cardiovascular morbidity and mortality among the patients with type 2 diabetes. With B12 supplementation homocysteine level can be reduced .Type 2 diabetes as a metabolic syndrome may show improvement in glycaemic control with Vitamin B12 therapy as there is correction of hyperhomocysteinemia. In studies it is proved that combination of vit B12, folic acid and vit B6 are effective for hyperhomocysteinemia.There are no such separate trials on the use of vit B12 alone. This therapy may be used in large number of type 2 uncontrolled diabetic hyperhomocysteinemic patients.

this study was planned with following objectives to study effect of Vitamin B12 supplementation on glycaemic control in poorly controlled hyperhomocysteinemic type 2 diabetic patients

  1. Glycaemic control measured by levels of glycosylated haemoglobin (HbA1c) at baseline and 4 weeks
  2. Fasting blood sugar level at baseline and 4 weeks
  3. Serum homocysteine/ vitamin B12 levels at baseline and 4 weeks
  4. Serum lipid profile at baseline and 4 weeks

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Vitamin B12 Deficiency Hyperhomocysteinemia Dietary Supplement: METHYLCOBALAMIN 500 micrograms Not Applicable

Detailed Description:

After approval from Institutional Ethics Committee, patients not responding adequately to oral anti-diabetic agents were recruited from Medicine out patient department (OPD) with the help of treating physician. Patient were first screened for serum homocysteine/vitamin B12 level along with all baseline investigations. Those having serum homocysteine level more than 15 umol/L or vitamin B12 level less than 223pg/ml were enrolled in this study. Due to high cost for investigation serum homocysteine level was measured only in 6 patients and serum vitamin B12 level (cheaper test) was measured in 14 patients with prior permission from Ethics Committee. Patients were given all the information about Vitamin B12 (methylcobalamin) including adverse effects. A written informed consent was taken from each patient and those who were willing to participate in study were enrolled in this study. All the information was recorded in case report forms.

There were two groups of poorly controlled patient; one group (DRUG GROUP) received methylcobalamin 500 ug daily with their usual antidiabetic therapy and the other group (CONTROL GROUP) received suitable antidiabetic drug therapy as prescribed by treating physician. Methylcobalamin 500ug was given once daily for the period of 4 weeks and were followed-up at 4 weeks. At Baseline all the investigations were carried out as follows:

Study Flow Chart

Baseline Serum Homocysteine.n=6 (DRUG GROUP), Serum Vitamin B12, n=14 (DRUG GROUP), n=18 (CONTROL GROUP) Body weight, height, Blood pressure,glycosylated hemoglobin (HbA1c) level, Blood sugar-Fasting/Postprandial, Serum lipid profile( to measure the effect of Vitamin B12), Blood urea, Serum creatinine, Serum Bilirubin, Serum glutamate oxaloacetate transaminase (SGOT),Serum glutamate pyruvate transaminase (SGPT), Alkaline phosphatase ( to rule out hepatic or renal dysfunction ), Routine urine examination for albumin, Electrocardiogram (ECG):to rule out cardiac abnormality viz, IHD, arrhythmias

4 Weeks Body weight, Blood pressure, glycosylated hemoglobin(HbA1c) level, Blood sugar-Fasting/Postprandial, Serum lipid profile, Serum homocysteine/ serum vitamin B12, Urine albumin examination

After enrollment of patient for study, All the baseline investigations will be carried out at Central Clinical Laboratory except glycosylated haemoglobin which was carried out at department of Pharmacology and homocysteine estimation which was carried out in an accredited laboratory. ECG, Blood pressure recording was carried out in Department of Medicine.

Reporting of Adverse effects: All patients had been given checklist of adverse effect of vitamin B12. Information of adverse drug reactions (ADRs ) was taken in next follow-up. If patients are unable tolerate adverse drug reactions they were advised to contact any of investigators at any time. Contact numbers of investigators was mentioned on patient information sheet.

Expected adverse drug reactions of vitamin B12 : Anorexia, Nausea, Vomiting, Diarrhea and Rash

Sample Size Calculation and statistical analysis:

Sample size of 20 for each group was calculated in the ratio of 1, power 80 %, considering 10 fold difference of drug effect in vitamin B12 group and control group by using Open Epi 2.3(2009). Randomization was done with the help of randomization software Rando 1.2,2004. Statistical analysis was done by using Open Epi 2.3(2009) and Microsoft Excel.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 38 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of Vitamin B12 Supplementation on Glycaemic Control in Uncontrolled Hyperhomocysteinemic Type 2 Diabetic Patients
Study Start Date : October 2010
Actual Primary Completion Date : May 2015
Actual Study Completion Date : May 2015


Arm Intervention/treatment
Active Comparator: Vitamin B12 and Antidiabetics
Tablet Methylcobalamin 500 ug once daily with other usual antidiabetic drugs
Dietary Supplement: METHYLCOBALAMIN 500 micrograms
Tab Methycobalamin 500 ug will be given with other regular antidiabetic drugs
Other Name: Vitamin B12

No Intervention: antidiabetics
Only regular antidiabetic drugs will be given



Primary Outcome Measures :
  1. To compare the change in HbA1c levels (%) with vitamin B12 supplementation in poorly controlled type 2 diabetic patients [ Time Frame: baseline and 4 weeks ]

Secondary Outcome Measures :
  1. To compare the change in high density lipoprotein(HDL),low density lipoprotein(LDL) and total cholesterol in mg/dL with vitamin B12 supplementation in poorly controlled type 2 diabetic patients [ Time Frame: baseline and 4 weeks ]
  2. To compare the change in fasting and postprandial blood sugar levels (mg/dL) with vitamin B12 supplementation in poorly controlled type 2 diabetic patients [ Time Frame: baseline and 4 weeks ]
  3. To compare the change in serum homocysteine level (micromol/L) with vitamin B12 supplementation in poorly controlled type 2 diabetic patients [ Time Frame: baseline and 4 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age between 30 -70 years
  2. Sex: Male/ Non-lactating female
  3. Glycosylated hemoglobin (HbA1c) > 8
  4. Serum Homocysteine > 15 umol / L or vitamin B12 less than 223pg/ml

Exclusion Criteria:

  1. Age < 30 yrs.
  2. Pregnancy
  3. Lactating mother
  4. Patient with Insulin dependent diabetes mellitus
  5. Severe and Complicated diabetes mellitus
  6. Patient with hepatic or renal dysfunction

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02540642


Locations
Layout table for location information
India
Smt Kashibai Navale Medical College and Hospital
Pune, Maharashtra, India, 411041
Sponsors and Collaborators
Smt. Kashibai Navale Medical College and General Hospital
Investigators
Layout table for investigator information
Principal Investigator: YOGENDRA N KECHE, MD SMT KASHIBAI NAVALE MEDICAL COLLEGE
Layout table for additonal information
Responsible Party: Dr Yogendra Keche, Associate Professor, Smt. Kashibai Navale Medical College and General Hospital
ClinicalTrials.gov Identifier: NCT02540642    
Other Study ID Numbers: SKNMC No./Ethics/App/2010/45
First Posted: September 4, 2015    Key Record Dates
Last Update Posted: March 15, 2018
Last Verified: March 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Hyperhomocysteinemia
Vitamin B 12 Deficiency
Vitamin B Deficiency
Avitaminosis
Deficiency Diseases
Malnutrition
Nutrition Disorders
Amino Acid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Malabsorption Syndromes
Metabolic Diseases
Vitamin B 12
Vitamins
Micronutrients
Physiological Effects of Drugs
Vitamin B Complex